Physician profile
Matthew Porter
NPI 1598811986
$3,459.62
in general payments reported to CMS, 2019-2025
22 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $216 · 2021: $1,592 · 2022: $73.84 · 2023: $71.42 · 2024: $737 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,373.84 | 2021 | |
| Abbott Laboratories | $522.54 | 2019-2025 | Eterna |
| Abbvie INC. | $371.19 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $128.77 | 2024-2025 | |
| Pfizer INC. | $125.00 | 2019 | |
| Collegium Pharmaceutical, INC. | $121.82 | 2019-2020 | |
| Pylant Medical | $118.26 | 2021 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.13 | 2019-2020 | |
| Allergan, INC. | $73.08 | 2019-2021 | |
| Boston Scientific Corporation | $70.38 | 2024 | Wavewriter Alpha Prime 16 |
| Zimmer Biomet Holdings, INC. | $66.60 | 2021 | |
| Nevro Corp. | $54.34 | 2020 | |
| Depuy Synthes Sales INC. | $46.01 | 2024-2025 | Monovisc, Orthovisc |
| Bioventus LLC | $38.17 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $37.31 | 2024 | Sprint Pns System |
| Alafair Biosciences, INC. | $35.67 | 2022 | |
| Medtronic, INC. | $34.41 | 2025 | Intellis Adaptivestim |
| Abiomed | $30.78 | 2024 | Impella |
| Dexcom, INC. | $13.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.96 | 2019 | |
| Saluda Medical Americas, INC. | $12.43 | 2023 | Evoke Scs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.